Navigation Links
INC Research and Debiopharm Group(TM) Announce Strategic Partnership
Date:7/26/2011

LAUSANNE, Switzerland and RALEIGH, North Carolina, July 26, 2011 /PRNewswire/ --


INC Research, LLC, a therapeutically focused contract research organisation (CRO) with a trusted process for delivering reliable results, and Debiopharm Group™ ("Debiopharm"), a Swiss-based global biopharmaceutical group with a focus on drug development and companion diagnostics, today announced a strategic partnership. Under the terms of the agreement, Debiopharm will entrust INC Research with the management of a clinical study linked to an important project in Debiopharm's pipeline. Both parties have furthermore agreed on a framework partnership pertaining to future clinical studies to be conducted by INC Research for Debiopharm.

"Debiopharm's reputation and success in establishing partnerships is aligned very closely with our vision of creating strategic relationships that improve the speed, efficiency, and quality of drug development," said Kelvin Logan, Ph.D., president INC Research Europe and Asia Pacific, who added "we are pleased to offer our therapeutic expertise along with our experience in conducting trials globally to support Debiopharm's drug development efforts in bringing innovative medicines to market more quickly and efficiently."

"It is through our successful partnerships that we have been able to build and maintain a truly leading global biopharmaceutical development group, while supporting and conducting several clinical development programmes on a continuous basis," said Dr Rolland-Yves Mauvernay, President and Founder of Debiopharm. "This partnership with INC Research will significantly help us in our endeavours to conduct our clinical development programmes efficiently, which in turn will enable us to continue to fuel our pipeline with important new medicines."

INC Research's clinical delivery alliance structures can include complete management of a compound or therapeutic area; management of a specific function or set of critical processes; sharing in the risk and reward of a compound's performance; or acting as the sole source development partner for a customer. The company's proven experience with process-driven clinical research methods and its popular metrics-based Trusted Process® provides the foundation for successful strategic alliances.

About Debiopharm Group

Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III as well as earlier stage candidates. It develops its products for global registration and maximum commercial potential. The products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm is also active in the field of companion diagnostics with a view to progressing in the area of personalised medicine. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs. For more information on Debiopharm Group™, please visit: http://www.debiopharm.com.

About INC Research, LLC

INC Research is a therapeutically focused contract research organisation with a high performance reputation for conducting global clinical development programmes (http://www.incresearch.com/Global/Global-CRO.aspx) of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV (http://www.incresearch.com/Services/Contract-Research-Organization.aspx) programmes in therapeutic areas of specialty (http://www.incresearch.com/Therapeutic/Clinical-Trials-Services.aspx), and in innovative pediatric and women's health trials. The company's Trusted Process® (http://www.incresearch.com/TheTrustedProcess/Clinical-Trials-Outsourcing.aspx) methodology and therapeutic foresight leads customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, NC. For more information please visit http://www.incresearch.com or follow us at http://twitter.com/#!/inc_research.

Contacts

Debiopharm S.A.
Maurice Wagner, Ph.D.
Director Corporate Affairs & Communication
Tel.:+41(0)21-321-01-11
E-mail: mwagner@debiopharm.com

Additional Media Contacts

In London
Maitland
Brian Hudspith
Tel.: +44(0)20-7379-5151
bhudspith@maitland.co.uk

In New York
Russo Partners, LLC
Martina Schwarzkopf, Ph.D.
Account Executive
Tel.: +1-212-845-4292
Fax:  +1-212-845-4260
martina.schwarzkopf@russopartnersllc.com

INC Research
Kelly Foster
kelly@johnkellyfoster.com
+1-619-224-1261



'/>"/>
SOURCE The Debiopharm Group
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. NIH Funds $1M Research at Quest Product Development and University of Colorado for New Digitally-Controlled Endoscopes
2. Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
3. Association of Clinical Research Organizations (ACRO) Welcomes Clinilabs and RPS as New Members
4. Melior Enters Research Collaboration with AstraZeneca
5. UC Riverside researcher develops novel method to grow human embryonic stem cells
6. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
7. Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration
8. US Oncology Appoints Stephen Smith Vice President/General Manager Research and Personalized Science Services
9. Cyntellect to Collaborate With the Burnham Institute for Medical Research
10. Memory Pharmaceuticals Closes Final Tranche of Equity Financing with The Stanley Medical Research Institute
11. MD Anderson Becomes a GeneGo Center of Excellence Using MetaCore for Oncology Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... ... Last week, Callan Capital, an integrated wealth management firm specializing in asset ... Diego Life Science event at the Estancia La Jolla Resort and Spa. , Over ... Dr. Rich Heyman, former CEO of Aragon and Seragon, and Faheem Hasnain, former CEO ...
(Date:5/23/2016)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a ... of Directors has approved the payment of a quarterly cash ... The cash dividend of $0.24 per share will ... of record as of the close of business on June ... of the Board of Directors and may be adjusted as ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... focused on molecular nanotechnology, announced the winners for the 2015 Foresight Institute Feynman ... Feynman, are given in two categories, one for experiment and the other for ...
(Date:5/20/2016)... ... May 20, 2016 , ... Korean researchers say Manumycin A triggers ... a new way to treat the disease. Surviving Mesothelioma has just posted an article ... from several Korean institutions based their mesothelioma study on the fact the Manumycin A, ...
Breaking Biology Technology:
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
Breaking Biology News(10 mins):